Author Archives: Kate Hutchinson

Ortek Therapeutics Announces New Patent for Microbiome Technology

Posted on by
Reply

Rosyln Heights, NY-based Ortek Therapeutics announced that the U.S. Patent and Trademark Office has awarded a patent for new methods to use new compositions to prevent or treat drug-resistant bacteria and suppress body odor.

U.S. Patent 9,370,476, was issued to The Research Foundation of State University of New York, an Ortek licensing partner, and is directed to topical application of a zinc and arginine-based composition. Ortek holds exclusive international licensing rights to this patent, which was developed at Stony Brook University. Ortek has a long-standing relationship with Israel Kleinberg DDS, PhD, DSc, who led the development of this new technology and is the Director of the Division of Translational Oral Biology at Stony Brook University.

Traverse Biosciences to collaborate with SUNY Upstate Medical University

Posted on by
Reply

Traverse Biosciences has announced a collaboration with SUNY Updated Medical University on a $164,689 Peer Reviewed Medical Research Program (PRMRP) Discovery Award from the U.S. Department of Defense. The research will be led by Gary Nieman, Associate Professor and Senior Research Scientist in the Department of Surgery and will evaluate the effectiveness of the company’s lead drug candidate, TRB-N0224, to treat acute lung injury, including acute respiratory distress syndrome (ARDS). Read more here.

TraverseBioLogo2

Next HHS SBIR/STTR Application Deadline 9/6 – Get Started Today

Posted on by
Reply

September 6 is the next HHS SBIR/STTR standard deadline. Talk to an HHS SBIR/STTR program manager today for advice: http://bit.ly/SBIR_IC_Contacts

The next HHS SBIR/STTR application deadline is less than two months away on Tuesday, September 6, 2016 at 5 pm local time. (Note – the standard deadline falls on September 5, a federal holiday, so the revised deadline is September 6).

Make sure you are registered! The 5-step registration process may take 6 – 8 weeks, so it is important to start now. All registrations must be completed prior to the application being submitted, and the System for Awards Management (SAM) registration must be updated annually. Learn more about the five required registrations, here.

Don’t be shy – speak to an HHS SBIR/STTR Program Manager! It is critical for success that applicants speak to a program manager before submitting! You should send the program manager a non-confidential abstract or executive summary of your research topic, including a description of your technology, which may include your specific aims. After you connect via email, you and the program manager may decide to set up a call to discuss your application in more detail. For questions about who to contact, please email sbir@od.nih.gov.

ASSIST vs. Downloadable Forms – You may submit your application using ASSIST or the Downloadable Forms method, starting on March 5, 2016. Please select the “Apply Online Using ASSIST” button, or the “Apply Using Downloadable Forms” button within the SBIR/STTR solicitation. View the ASSIST webinar materials here.

Be sure to use the Annotated SF424 SBIR/STTR Form Set in conjunction with the SF424 R&R SBIR/STTR Application Guide (FORMS-D) to guide you step-by-step through the application process. Applicants also find the Top 5 Most Common eRA Commons Errors and the SBIR Sample Application from NIAID helpful. All resources can be found on our Resources page.

Remember – The standard due dates occur on September 5, January 5, and April 5. The standard due dates apply to all SBIR/STTR solicitations that follow the Standard Due Dates, including the SBIR/STTR Omnibus solicitations and the Commercialization Readiness Pilot Program solicitations. You can find all solicitations here.

 

Intensity Therapeutics, Inc. Raises $10 Million Series A

Posted on by
Reply

Intensity

 

 

Intensity Therapeutics has announced that it has secured $10 million in new capital from a Series A preferred stock financing. Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors and family offices.

Lead by President and CEO Lewis H. Bender, the company is developing a proprietary cancer immunotherapy products. In a statement Bender said, “Our lead drug, INT230-6, has shown strong results in severe murine models of metastatic cancer via a combination of direct tumor killing and immune system activation.” According to Bender, “Proceeds will be used to fund operations, manufacture the clinical supplies, permit the needed regulatory filings and conduct a series of clinical trial cohorts in cancer patients with various tumor types.”

The company has also announced the addition of Dr. Decalan Doogan former Senior Vice President and Head of worldwide drug development at Pfizer and Emer Leahy, Ph.D., CEO of PsychoGenics will join Intensity’s Board of Directors. More information about Intensity Therapeutics can be found on the company’s website: www.intensitytherapeutics.com.

BIO 2016

Posted on by
Reply

bio2016c

The Center for Biotechnology team recently ventured out to San Francisco for BIO’s annual International Convention. Through the support of Empire State Development and the Long Island Bioscience Hub, the Center for Biotechnology was able to support six Long Island emerging biotech companies to attend the meeting: Alpha-1 Biologics Corporation, Codagenix, Inc., DepYMed, Inc., iCell Gene Therapeutics, PhD Skin Care LLC and Vela Therapeutics. These companies were joined in the New York Pavilion by more than two dozen other companies and entities representing New York State.

Long Island and New York City regional companies Alpha-1 Biologics, Vela Therapeutics, Intrommune Therapeutics, PainQX, Serendipity Biotech, ENB Therapeutics, and QuickSilver Biosystems all were recipients of grants from Empire State Development and NewYorkBio which also assisted their participation in the event. These companies were tapped to present in the New York Pavilion along with six other companies from upstate New York.

Envisagenics, ENB Therapeutics, PainQx, QuickSilver and Abcombi BioSciences, all New York State Companies, were invited to participate in the BIO 2016 “Start-Up Stadium” which provide start-up companies with the opportunity to pitch to key members of the investment community, venture philanthropy groups, and BIO attendees. The participating investors provided live feedback and judged the sessions.

In addition, six Long Island Bioscience Hub faculty members were invited to participate in the meeting for the first time. These NIH-REACH program supported faculty attended with the goal to learn more about the commercialization process, how it applies to their translational research, and to engage in the partnering process and meet with potential strategic contacts. Center staff met with over 40 strategic partners over the course of the meeting and follow up is underway.

bio2016b